Daily non-political popular news in brief.

Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?

New research by scientists in Taiwan has shown that an 800-year-old formula, 4 Agents Decoction (Si Wu Tang), does not significantly reduce menstrual pain after three cycles of treatment; however, a beneficial effect may be present after a longer treatment. The dosage regimen and treatment length used in this study are not associated with adverse reactions. The results are published in the August 15 issue of the online, open-access journal PLoS ONE.

Read more »

Keywords: agents, decoction, tang, efficacious, treating, primary, dysmenorrhea, agent, efficaciou

« Previous | Next »

Similar news on "Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?":

1. Is 4 agents decoction efficacious in treating primary dysmenorrhea?
   08-21-2007 · EurekAlert!
   New research by scientists in Taiwan has shown that an 800-year-old formula, Four Agents Decoction (Si Wu Tang), does not significantly reduce menstrual pain after three cycles of treatment; however, a beneficial effect may be present after a longer treatment. The dosage regimen and treatment length used in this study are not associated with adverse reactions. The results are published in the Aug. 15 issue of the online, open-access journal PLoS ONE.
   Similar news · Read more »
   
2. Novel gallium compound may offer treatment for lymphoma patients with resistant disease
   12-11-2006 · EurekAlert!
   Christopher Chitambar, M.D., a physician researcher at the Medical College of Wisconsin Cancer Center in Milwaukee, has identified a compound that may be effective in treating forms of non-Hodgkin's lymphoma (a cancer of the lymphatic system) that are resistant to certain therapies. The new agent could also offer the advantages of being administered orally, rather than intravenously, making it more convenient than intravenous agents.
   Similar news · Read more »
   
3. 'Modular' leukemia drug shows promise in early testing
   06-28-2007 · EurekAlert!
   A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows. The agent represents a new class of agents called small modular immunopharmaceuticals. Called CD37-SMIP, the agent targets a protein called CD37 on the surface of these leukemia cells.
   Similar news · Read more »
   
4. Finnish scientists discovered a new approach to treat virus-induced lymphomas
   03-15-2007 · EurekAlert!
   Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi’s sarcoma and primary effusion lymphoma (PEL). PELs are aggressive lymphomas with reported median survival time shorter than six months after diagnosis. Researchers at the University of Helsinki have discovered that activation of the p53 pathway offers a novel effective treatment modality for KSHV-infected lymphomas.
   Similar news · Read more »
   
5. Evidence links anemia drugs with leukemic transformation in patients with primary myelofibrosis
   12-10-2007 · EurekAlert!
   Mayo Clinic researchers today reported the discovery of a link between erythropoiesis-stimulating agents and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis.
   Similar news · Read more »
   
6. Cancer stem cells similar to normal stem cells can thwart anti-cancer agents
   06-15-2007 · EurekAlert!
   Current cancer therapies often are thwarted because they cannot eliminate a small reservoir of multiple-drug-resistant tumor cells. Researchers at the University of Pittsburgh School of Medicine suggests that for chemotherapy to be truly effective in treating lung cancers, for example, it must be able to target a small subset of cancer stem cells, which they have shown share the same protective mechanisms as normal lung stem cells.
   Similar news · Read more »
   
7. Researchers develop novel method for treatment of sickle cell disease
   11-07-2006 · EurekAlert!
   Virginia Commonwealth University researchers have developed a unique anti-sickling agent that may one day be effective in treating sickle cell disease, a painful and debilitating genetic blood disorder that affects approximately 80,000 Americans.
   Similar news · Read more »
   
8. A search for protection against chemotherapy cardiotoxicity
   12-20-2007 · EurekAlert!
   The use of several chemotherapeutic agents in oncology is limited by their cardiac toxicity. Recent experimental studies suggest that recombinant human erythropoietin (rhEPO) can be considered as a protective agent against cardiac ischemic injury. Here we show that pretreatment by rhEPO protects myocardium against cardiotoxicity induced by acute doxorubicin or trastuzumab exposure, using the isolated rat heart model. Further clinical investigations are now needed to explore the potential benefit of rhEPO in oncology.
   Similar news · Read more »
   
9. Ireland Cancer Center researchers advance lung cancer treatment
   04-23-2007 · EurekAlert!
   Researchers at the Ireland Cancer Center of University Hospitals Case Medical Center have developed methods for treating lung cancer cells that have become resistant to new anti-cancer agents, such as Tarceva (erlotinib). Using a new second-generation of Tarceva-like medications, researchers can overcome the drug resistance, and such drugs are now in development including in clinical trials at the Ireland Cancer Center.
   Similar news · Read more »
   
10. Researchers create new method for uncovering natural products from mystery 'orphan genes'
    01-26-2007 · EurekAlert!
    Microorganisms have a proven track record for producing powerful molecules useful in antibiotics, as anticancer agents, and in treating human diseases.
    Similar news · Read more »